Business Wire

CA-FORESCOUT

Share
U.S. Department of Defense Awards Forescout New Comply-to-Connect Contract as Program Enters Step Four

Forescout, a global cybersecurity leader and a key provider of cybersecurity solutions to the U.S. Department of Defense (DoD), announced today that it secured a new contract with the DoD as it enters year four of the highly successful Comply-to-Connect (C2C) program. The program’s next stage will be to configure delivered capabilities to enforce zero trust access principles across the DoD Information Network (DoDIN) enterprise and bring the DoD closer to the goals set forth in the Department’s Zero Trust Strategy.

As advocated by the Defense Information System Agency (DISA) C2C Program Management Office (PMO), the new contract also delivers additional capabilities to the C2C platform that revolutionize security of Operational Technology networks and integrates risk management and decision making into the existing C2C platform. This addition further positions the DoD to apply NIST zero trust principles to millions of devices across the enterprise. Implementation of zero trust principles using Forescout’s C2C capabilities is already being accomplished in some areas of the Army, via an initiative being taught at Fort Gordon school houses and referenced in Defense Acquisition University.

With the first three steps of the program – visibility, compliance assessment, and automated remediation – well underway, administrators can now use Forescout’s orchestration capabilities to manage policy enforcement points to create the desired effects on an individual user/device/access request basis. Additionally, Forescout’s continuous monitoring capabilities are at work to ensure connected devices don’t fall out of compliance due to files getting corrupted, simple administrative mistakes, or malicious adversarial actions, all of which occur daily on the DoDIN.

C2C is one of the largest government cybersecurity initiatives in the world delivering enterprise scale capabilities for managing cyber operational risk. With the program now in its fourth year, automated control of access to and within the DoDIN will ensure that each network user has the access necessary to achieve their mission without exposing other users to threats that could impact their ability to complete their mission.

“We are proud to once again be trusted by so many organizations to secure the backbone of their operations: the networks that connect everything,” said Barry Mainz, CEO, Forescout. “Each DoDIN user should have confidence that their slice of the network is secure and ready for them to accomplish their mission. That’s what we are delivering through C2C.”

Today, the Forescout platform provides comprehensive capabilities for the DoD’s C2C security framework that enables the critical first pillar of DISA’s zero trust program called Thunderdome. This includes:

  • Network-based discovery and classification of assets, including an expanding set of “unmanaged” assets that are unable to operate agents (C2C Steps 1 and 2)
  • Integration with other enterprise solutions such as Identity, Credential, and Access Management (ICAM); Security Information Event Management (SIEM); and Vulnerability Assessment products to automate compliance of the cybersecurity posture and establish trust for every connecting asset (C2C Step 3)
  • Orchestration of policy enforcement points across the infrastructure to enforce network access control and segmentation of assets as well as complete situational awareness of the network posture (C2C Steps 4 and 5)

“We look forward to introducing cloud-based advanced threat analysis tools into the C2C program’s portfolio of capabilities and adding further value on DoD’s zero trust journey,” added Mainz. “We’ve really just begun to unleash the power of our platform within the DoD. The best is still ahead.”

Additional Resources

About Forescout

Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats. www.forescout.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230914036853/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e

AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release

Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its

Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release

4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye